GLPG
Galapagos N.V.
NASDAQ · Healthcare · Biotechnology · BE
$27.98
+1.71%Year over year
Reported trailing growth
- Revenue
- +262.2%
- EBITDA
- +167.6%
- EBIT
- +224.8%
- EPS
- +383.1%
- Free cash flow
- -19.7%
- Operating cash flow
- -25.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +66.4%
- EBITDA
- +352.6%
- EBIT
- +366.2%
- Net income
- +23.1%
- EPS
- +333.0%
- Free cash flow
- +49.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026